Tools for Practice Outils pour la pratique


#409 Less than 140, 130, or 120? Counting down to the optimal systolic blood pressure target.


CLINICAL QUESTION
QUESTION CLINIQUE
What are the benefits and harms of lower systolic blood pressure (SBP) targets?


BOTTOM LINE
RÉSULTAT FINAL
In patients with hypertension, a target SBP <130 mmHg over 3 years reduces cardiovascular events to 5.3% from 7.1% with <140 mmHg but increases the risk of side-effects (like hypotension or electrolyte abnormality) to 7.2% from 5.4%.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • At least 5 systematic reviews in past 5 years.1-6 All results statistically significant unless stated.
  • Focusing on individual participant-level meta-analysis of 6 largest, randomized controlled trials (RCTs) with 80,676 participants (average age 64, 44% with 10-year cardiovascular risk ≥20%) comparing “intensive” (<120-130) versus “standard” (<140-150) SBP target.1
    • At 3.2 years:
      • Cardiovascular death: 1.1% versus 1.5% (standard), number needed to treat (NNT)=250.
        • All-cause death reduced, but event rates not reported.
      • Cardiovascular events: 5.3% versus 7.1% (standard), NNT=59.
      • Side-effects: 7.2% versus 5.4% (standard), number needed to harm (NNH)=56.
        • Examples:2 Hypotension (NNH=~500), acute kidney injury (NNH=~1600), syncope (NNH=~1700), injurious falls (NNH=~2900), electrolyte abnormality (NNH=~3200).
      • Intensive group required 0.5-2 additional BP medications.
    • Similar NNT for cardiovascular events in RCTs targeting SBP <120 mmHg (NNT=56) and <130 mmHg (NNT=61).
    • Similar efficacy and safety in patients with or without diabetes or stroke history.
  • Other systematic reviews with fewer patients: Similar results, but inconsistent effect on mortality.2-6
  • Quality of life: No clinically important differences.7-9
  • Limitations: No direct comparisons of SBP <120 versus <130. Differences in achieved SBP between RCTs with SBP target <120 (intensive 121 versus standard 135) versus target <130 (intensive 131 versus standard 146).

CONTEXT
CONTEXTE
  • Accurate SBP measurements are critical to avoid harm with intensive targets.
    • SPRINT trial: Optimal blood pressure measurement technique in clinic led to reported SBP ~7 mmHg lower than typical technique (121 versus 128 mmHg).10
    • Measurement technique tips available.11
  • Canadian11 and international12,13 hypertension guidelines:
    • Start medications at BP ≥140/90 mmHg (or ≥130/80 mmHg with cardiovascular disease or 10-year risk ≥20%);
    • Target SBP target <130 mmHg for all patients, if tolerated without bothersome side-effects.
  • In one study,1 patients valued cardiovascular events three times more than side-effects, but for some patients side effect concerns may outweigh potential benefits.


Mike Geoghegan March 14, 2026

Interesting

Brian Dressler March 16, 2026

synergistic effects

Brian Dressler March 16, 2026

effects of gabapentin

Paul Brown March 16, 2026

Good information, it improves risk assessment

Robert Ramsey March 20, 2026

reinforces my practice

Tamunotonte Bob-Manuel April 25, 2026

How about diastolic BP?

Tamunotonte Bob-Manuel April 25, 2026

What is the target for diastolic BP

Anna Da Silva May 20, 2026

helpful to have home bp measurements measured accurately


Latest Tools for Practice
Derniers outils pour la pratique

#415 Blood Pressure Measurement Technique: Meaningful mistakes or minor details?

Does following recommended blood pressure measurement techniques impact the accuracy of readings?
Read Lire 0.25 credits available Crédits disponibles

#414 A Tough Nut to Crack: Does oral immunotherapy improve outcomes in peanut allergy?

In children with peanut allergy, does oral immunotherapy increase peanut tolerance, and what are the adverse effects?
Read Lire 0.25 credits available Crédits disponibles

#413 Itchy Beginnings: Can we calm infant eczema?

In infants under 2, how effective and safe are topical treatments for eczema?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Ricky D. Turgeon BSc(Pharm) ACPR PharmD
  • Samantha S Moe PharmD ACPR
  • Scott Garrison MD CCFP PhD

1. Guo X, Sun G, Xu Y, et al. Lancet. 2025;406:1009-19.

2. Whelton PK, O’Connell S, Mills KT, He J. Hypertension. 2024;81:2329-339.

3. Nozato Y, Nohara-Shitama Y, Kubozono T, et al. Hypertens Res. 2025;48:2527-36.

4. Saad M, Sohail MU, Waqas SA, et al. Prim Care Diabetes. 2025;19:422-5.

5. Saiz LC, Gorricho J, Garjon J, et al. Cochrane Database Syst Rev. 2022;11:CD010315.

6. Arguedas JA, Leiva V, Wright JM. Cochrane Database Syst Rev. 2020;12:CD004349.

7. O’Connor PJ, Narayan KMV, Anderson R, et al. Diabetes Care. 2012;35:1479-81.

8. Berlowitz DR, Foy CG, Kazis LE, et al. N Engl J Med. 2017;377:733-44.

9. Huang X, Zhang H, Li Y, et al. J Am Coll Cardiol. 2025;86:1392-401.

10. Drawz PE, Agarwal A, Dwyer JP, et al. JAMA Intern Med. 2020;180:1655-63.

11. Goupil R, Tsuyuki R, Santesso N, et al. CMAJ. 2025;197:E549-64.

12. Jones DW, Ferdinand KC, Taler SJ, et al. Hypertension 2025;82:e212-e316.

13. McEvoy JW, McCarthy CP, Bruno RM, et al. Eur Heart J. 2024;45:3912-4018.

Authors do not have any conflicts of interest to declare.